Volume 7 Issue 2 2021

ISSN 2454-3055

**INTERNATIONAL
JOURNAL OF
ZOOLOGICAL
INVESTIGATIONS**

***Forum for Biological and
Environmental Sciences***

Published by Saran Publications, India

Childhood Liver Cancer Hepatoblastoma: A Brief Review

Padmapriya V., Ashok K., Babu M., Janaki Devi V. and Mullai Nila K.*

Department of Microbiology and Biotechnology, Faculty of Arts and Science, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India

*Corresponding Author

Received: 24th August, 2021; **Accepted:** 17th September, 2021; **Published online:** 20th September, 2021

<https://doi.org/10.33745/ijzi.2021.v07i02.035>

Abstract: Hepatoblastoma (HPB) is, while rare, the most prevalent childhood liver tumour (LT). Full resection is a vital cure factor but most patients are treated for tumours (TR) that have not been identified. The treatment of neoadjuvant chemotherapy (CHEM) makes TR's of most cases resectable. Liver transplantation (LTP) is indicated in patients whose cancers (CA's) are unresectable following CHEM (in the absence of active unresectable metastatic disease). The interventional therapies may serve promising to decrease the TR size, lower the systemical toxicity, minimise hepatic transplantation (HTRP) and improve the viability of TR's resection for patients whose TR's remain resectable after standard CHEM.

Keywords: Hepatoblasma, Liver cancer, Chemotherapy

Citation: Padmapriya V., Ashok K., Babu M., Janaki Devi V. and Mullai Nila K.: Childhood liver cancer hepatoblastoma: A brief review. Intern. J. Zool. Invest. 7 (2): 562-565, 2021.

<https://doi.org/10.33745/ijzi.2021.v07i02.035>

Introduction

In infants, liver tumours (LTs) are uncommon. In part, owing to the lack of consensus on a classification scheme, their diagnoses can be difficult. Systemic core histopathological analysis of these tumours (TRs) undertaken as part of paediatric therapeutic collective guidelines has allowed the assessment of histological subtypes of particular clinical associations (Ishak and Glunz, 1967; Stocker and Ishak, 1987; Huhhes and Michels, 1992; Herzog *et al.*, 2000; Spector and Birch, 2012). Consequently, histopathology was used as a parameter for the risk-stratifying of patient care in the Children's Oncology Community (COG) guidelines in the US. In 2011, the COG LT's Committee sponsored the

2011 International Pathology Symposium to address histopathology and classification of paediatric LT's (especially HPB) and produce an international classification of paediatric LT's. Data have been released for international ranking of paediatric LT's (Haas *et al.*, 1989; Schnater *et al.*, 2003; Sharma *et al.*, 2017). In order to enhance the future patient care and production, the systematic, clinically relevant classification would allow new biological criteria and the TR genetics to be integrated into the common pathologic terminology (von Schweinitz, 2012).

Details on the histology of each childhood LC subtypes are as follow:

Solid TR liver cancer (LC) is HPB. This main LT is an unusual occurrence of only 50-70 new cases diagnosed in the United States, including half of all LT's in children per year (McLaughlin *et al.*, 2006; Kremer *et al.*, 2014; Maibach *et al.*, 2012). It happens in boys much more than in girls. Scientists don't know the cause of this condition. However, certain infants are at greater risk of HPB because of such inherited disorders (Exelby *et al.*, 1975; Hiyama, 2014). This includes: adenomatous disease, adenomate syndrome of the family and Aicardi syndrome. In pre-school aged girls, HPB is most often reported. In the first year of life, one half of all patients are diagnosed, the rest of whom are diagnosed by their third birthday (Rainier *et al.*, 1995; Roebuck and Perilongo, 2006; Tomlinson and Kappler, 2012; Czauderna *et al.*, 2014).

X-ray, CT scan, MRI scan and/or ultrasound may be performed for diagnosis and treatment control. Since diagnosing the HPB, it is staged depending on the size of the TR and the surgical removal of it. Around half of the TR's associated with HPB are minimal and can be treated with surgery alone (Stage I) (Pimpalwar *et al.*, 2002; Meyers *et al.*, 2012; Aronson *et al.*, 2014). The liver is a regenerating organ that will make procedure the greatest hope of a full treatment. When the TR has spread to the lymph node (Stage III), or to other areas of the body, mostly the lung (Stage IV), CHEM is used to shrink the TR before surgical resection. Children with relapsed TR's that did not grow beyond the liver may be candidates for HTRP (Lopez-Terrada *et al.*, 2009; Armengol *et al.*, 2011; Perilongo *et al.*, 2012).

Checking of a serum TR marker: HPB also releases a blood protein. Alpha-fetoprotein (AFP) levels can be used to assess whether there is any disease evidence or sign of a relapse (AFP level decrease), the reaction rate of the TR (increased levels of AFP). When used to shrink TR's prior to intervention, hepatoblastic disease responds well to CHEM agents. Cisplatin, fluorouracil, doxorubicin and vincristine constitute chemical

agents. Ifosfamide, dactinomycin and etoposide are all potential agents used (Doi, 1976; Lautz *et al.*, 2011; Heck *et al.*, 2013).

Diagnostic signs can include—(i) Lump or mass mostly on the right or middle side of the abdomen, (ii) Appetite loss, fatigue, weight loss irregular, diarrhoea, (iii) Skin colour changes: yellow skin and white eye jaundice, (iv) Discomfort in general, (v) Fever, rage, confusion, and (vi) Pain of the abdomen.

Statistics, threat factors, effects:

- Some 50-70 new cases per year in the US.
- 1% of all childhood CA's.
- 95% diagnosed before the age of four years.
- The condition can be treated alone by treatment in 50 per cent of cases.
- For the combined HPB levels, the 5-Year Survival rate is 60%-70%. The early-stage disease forecast is good with a survival of 90% for 5 years.

The primary LC in children is rare, with HPB's that constitute one per cent of all paediatric CA's becoming the most frequent LT's in children. HPB's are over 75%, and is primarily linked with the diagnostic and radiological advances achieved by the uniform pre-chirurgical disease measurement scheme (PRETEXT), which optimises the chemical and surgical regimen (Heck *et al.*, 2013). The average survival rate is 75%. Fortunately, most HPB's lead to cisplatin treatment, and after CHEM, most CA's may be resectable. Liver transfer is an option for TR's in PRETEXT stage I-III with important vascular structural structures or in multifocal PRETEXT stage IV (Perilongo *et al.*, 2009). Although results were positive for normal risk cases, for advanced, metastatic and chronic illnesses, the forecast was low. Therapies to these children at greater risk are also a problem to refine (Czauderna and Garnier, 2018).

HPB is an embryonic TR, and may have histologenic and mixed epithelial and stromal

portion heterogeneity (De Ioris *et al.*, 2008). The epithelial part may be foetal hepatocytes or primitive hepatocytes. In light of molecular research, it is understood that an active unrelated TR, a malignant Rhabdoid TR, may be diagnosed by molecular validation of SMARCB1 deletions and a scarcity of the IN I-1 protein expression, a part of the SWIS/SNF chromatin reshuffling method, currently represents a significant portion of small-cell undifferentiated LT's (SCUDs) (Buendia, 2002).

A more sensitive molecular classification of hepatic TR's ensures that standard classifications of hepatitis TR's must also be made, combining the systematic use of immunostainers and molecular assays to better identify rare, targeted, malignant hepatitis TR's. Cured mutations or deletions in CTNNB1, encoding beta catenin in Wnt signal pathway, have been seen to date in molecular studies of HPB's. There are also reports of other mutations in the Wnt pathway genes such as APC, AXIN1 and AXIN2 (Yang *et al.*, 2019). Whole exome experiments have demonstrated that somatic mutations in HPB are not currently targeted in clinical conditions. TR classification tests may be helpful with transcriptome and methylation, but small trials have been conducted and not used to date in clinical practise (Giardiello *et al.*, 1996).

This new section highlights the many difficulties in the understanding and clinical treatment of paediatric LT's, focusing primarily on hepato-blastoma (Giardiello *et al.*, 1996). Further studies are needed to cover a variety of subjects including but not limited to:

- Update on clinical treatment (HPB's) for paediatric LT's, centred on high-risk therapies.
- The use of stratification biomarkers in low and high-risk groups.
- Update of HPB pathological and molecular classification.
- Molecular trials distinguishing juvenile hepatocellular carcinoma (HCC) and other rare childhood LC's from HPB.

- Role of tailored genome in the discovery of therapeutic and germ line mutations targets.

Conclusion

The primary TR resection (and metastatic sites, if applicable) is the objective for curative therapy of patients with HPB. CHEM can be used to make most of them resectable when TR's are thought to be non-resectable at diagnosis. LTP is indicated in patients who do not experience an advanced metastatic disease but who do not have primary TR's suitable for surgical resection. It is reasonable that intervention strategies can be an effective means to minimise tumour size, decrease systemic toxicity, and enhance TR resectability in patients with an early-stage unresectable disease.

References

- Armengol C, Cairo S, Fabre M and Buendia MA. (2011) Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. *Int J Biochem Cell Biol* 43(2): 265-270.
- Aronson DC, Czauderna P, Maibach R, Perilongo G, and Morland B. (2014) The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. *J Indian Assoc Pediatr Surgeons* 19(4): 201.
- Buendia MA. (2002) Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. *Med Pediatr Oncology* 39(5): 530-535.
- Czauderna P and Garnier H. (2018) Hepatoblastoma: current understanding, recent advances, and controversies. *F1000Res*. 7: 53.
- Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH and Meyers RL. (2014) Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. *Curr Opin Pediatr*. 26(1): 19-28.
- De Ioris, Brugieres M, Zimmermann L, Keeling A, Brock P, Maibach R, Pritchard J, Shafford L, Zsiros J, Czauderna P and Perilongo G. (2008) Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. *Eur J Cancer* 44(4): 545-550.
- Doi I. (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. *Gan*. 67(1): 1-10.
- Exelby PR, Filler RM and Grosfeld JL. (1975) Liver tumors in children in the particular reference to

- hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey-1974. *J Pediatr Surg.* 10(3): 329-337.
- Giardiello FM, Petersen GM, Brensinger JD, Luce MC, Cayouette MC, Bacon J, Booker SV and Hamilton, S. R. (1996) Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. *Gut* 39(6): 867-869.
- Haas JE, Muczynski KA, Krailo M, Ablin A, Land V, Vietti T J and Denman HG. (1989) Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. *Cancer* 64(5): 1082-1095.
- Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P and Ritz B. (2013) Case-control study of birth characteristics and the risk of hepatoblastoma. *Cancer Epidemiol.* 37(4): 390-395.
- Herzog CE, Andrassy RJ and Eftekhari F. (2000) Childhood cancers: hepatoblastoma. *Oncologist* 5(6): 445-453.
- Hiyama E. (2014) Pediatric hepatoblastoma: diagnosis and treatment. *Translat Pediatr.* 3(4): 293.
- Hughes LJ and Michels VV. (1992) Risk of hepatoblastoma in familial adenomatous polyposis. *Am J Med Genetics* 43(6): 1023-1025.
- Ishak KG and Glunz PR. (1967) Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. *Cancer* 20(3): 396-422.
- Kremer N, Walther AE and Tiao GM. (2014) Management of hepatoblastoma: an update. *Curr Opin Pediatr.* 26(3): 362-369.
- Lautz TB, Ben-Ami T, Tantemsapya N, Gosiengfiao Y and Superina RA. (2011) Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. *Cancer* 117(9): 1976-1983.
- López-Terrada D, Cheung SW, Finegold MJ and Knowles BB. (2009) Hep G2 is a hepatoblastoma-derived cell line. *Human Pathol.* 40(10): 1512.
- Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall'Igna P, Otte JB, Camargo BD, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P and Perilongo G. (2012) Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. *Eur J Cancer* 48(10): 1543-1549.
- McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC and Zdeb MS. (2006) Maternal and infant birth characteristics and hepatoblastoma. *Am J Epidemiology* 163(9): 818-828.
- Meyers RL, Czauderna P and Otte JB. (2012) Surgical treatment of hepatoblastoma. *Pediatr Blood and Cancer* 59(5): 800-808.
- Otte JB, Goyet JDVD and Reding R. (2005) Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. *Pediatr Transplant.* 9(5): 557-565.
- Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G and Czauderna P. (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. *New Eng J Med.* 361(17): 1662-1670.
- Perilongo G, Malogolowkin M and Feusner J. (2012) Hepatoblastoma clinical research: lessons learned and future challenges. *Pediatr Blood Cancer* 59(5): 818-821.
- Pimpalwar AP, Sharif K, Ramani P, Stevens M, Grundy R, Morland B, Llyod C, Kelly DA, Buckles JA and De Goyet, JDV. (2002) Strategy for hepatoblastoma management: transplant versus nontransplant surgery. *J Pediatr Surg.* 37(2): 240-245.
- Rainier S, Dobry CJ and Feinberg AP. (1995) Loss of imprinting in hepatoblastoma. *Cancer Res.* 55(9): 1836-1838.
- Roebuck DJ and Perilongo G. (2006) Hepatoblastoma: an oncological review. *Pediatr Radiol.* 36(3): 183-186.
- Schnater JM, Köhler SE, Lamers WH, von Schweinitz D and Aronson DC. (2003) Where do we stand with hepatoblastoma? A review. *Cancer: Interdiscip Int J Am Cancer Soc.* 98(4): 668-678.
- Sharma D, Subbarao G and Saxena R. (2017) Hepatoblastoma. In: *Seminars in diagnostic pathology*, WB Saunders, 34(2): 192-200.
- Spector LG and Birch J. (2012) The epidemiology of hepatoblastoma. *Pediatric Blood Cancer* 59(5): 776-779.
- Stocker JT and Ishak KG. (1987) Hepatoblastoma. In: *Neoplasms of the Liver*, (eds.) Okuda K. and Ishak K.G., Springer, Tokyo, pp.127-136.
- Tomlinson GE and Kappler R. (2012) Genetics and epigenetics of hepatoblastoma. *Pediatr Blood and Cancer* 59(5): 785-792.
- von Schweinitz D. (2012) Hepatoblastoma: recent developments in research and treatment. In: *Seminars in pediatric surgery*, WB Saunders, 21(1): 21-30.
- Yang T, Whitlock RS and Vasudevan SA. (2019) Surgical management of Hepatoblastoma and recent advances. *Cancers* 11(12): 1944.